Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Genomic Health Inc (GHDX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 1,018,770
  • Shares Outstanding, K 33,380
  • Annual Sales, $ 287,460 K
  • Annual Income, $ -33,310 K
  • 36-Month Beta 0.52
  • Price/Sales 3.45
  • Price/Book 6.84

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.16 +6.57%
on 11/03/16
33.96 -11.63%
on 11/14/16
+1.60 (+5.63%)
since 11/02/16
3-Month
26.39 +13.72%
on 09/12/16
33.96 -11.63%
on 11/14/16
+2.89 (+10.66%)
since 09/02/16
52-Week
22.00 +36.41%
on 03/17/16
35.79 -16.15%
on 01/06/16
-0.05 (-0.17%)
since 12/02/15

Most Recent Stories

More News
Genomic Health Announces Presentation of Multiple Oncotype DX® Studies at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium, Reinforcing Value of Genomics in Precision Medicine

Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present seven Oncotype DX® studies at the 39th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 6-10,...

Genomic Health to Present at the Credit Suisse 25th Annual Healthcare Conference

Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, chief operating officer and chief financial officer, will present at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale,...

Genomic Health (GHDX) Posts Wider-than-Expected Q3 Loss

Genomic Health (GHDX) reported third-quarter 2016 loss per share of 8 cents, an improvement from the year-ago quarter's loss figure of 36 cents. However, the loss figure was wider than the Zacks Consensus...

Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results

Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended September 30, 2016.

Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk of Metastasis and Mortality

Genomic Health, Inc. (NASDAQ: GHDX) today announced topline results from a large clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score(TM) (GPS). The study, performed in collaboration...

Comprehensive Economic Analysis Published in Reviews in Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads to Substantial Cost Savings and Increase in Active Surveillance

Genomic Health, Inc. (NASDAQ: GHDX) today announced publication in Reviews in Urology of a comprehensive economic analysis of the use of the Oncotype DX® Genomic Prostate ScoreTM (GPS) in low-risk prostate...

Genomic Health to Announce Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 1, 2016

Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 1 at 4:30 p.m. Eastern Time to discuss its third quarter 2016 financial...

The Top 100 U.S. In-Vitro Diagnostics Companies

Did you know?

Genomic Health Presents Robust Analytical Validation Study Results of Oncotype SEQ(TM) Liquid Biopsy Mutation Panel

Genomic Health, Inc. (Nasdaq: GHDX) today announced results from its successfully completed analytical validation study of Oncotype SEQ(TM) Liquid Select, which demonstrated that this liquid biopsy mutation...

Multiple Oncotype DX® Presentations at ESMO 2016 Congress Reinforce Its Unique Clinical Utility with Prospective Outcomes Results in Over 63,000 Breast Cancer Patients

Genomic Health, Inc. (Nasdaq: GHDX) today announced results from eight Oncotype DX® Breast Recurrence Score(TM) (RS) presentations at the European Society for Medical Oncology (ESMO) 2016 Congress in...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict...

See More

Support & Resistance

2nd Resistance Point 30.92
1st Resistance Point 30.47
Last Price 30.01
1st Support Level 29.38
2nd Support Level 28.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.